In a subgroup analysis conducted by quality score, we obtained significant results in high-quality studies that TP53 rs1042522 polymorphism increased the risk of cervical cancer in four models (CC + CG vs GG: OR = 1.707, 95% CI: 1.050-2.773, 95% PI: 0.200-14.539; GG + GC vs CC: OR = 3.213, 95% CI: 1.987-5.196; GC vs CC: OR = 2.677, 95% CI: 1.317-5.444, 95% PI: 0.133-53.997; GG vs CC: OR = 3.934, 95% CI: 2.210-7.001, 95% PI: 0.428-36.195). This evidence concerns the gene TP53 and cervical carcinoma.